Scientific Program Descriptions and Invited Speakers
Be inspired by the best and brightest in science. Internationally recognized scholars will present insights ranging from the personal to the global.
Monday, July 18
10:15 - 11:15 a.m.
Moderator: Vince Lee
Susan Hershenson, The Bill and Melinda Gates Foundation, U.S.A.
Application of Controlled Release and Drug Delivery Technology to Address Global Health Needs
Controlled release technology and innovative drug delivery systems have great potential to address many of the challenges in developing and delivering healthcare for low resource settings. The Bill and Melinda Gates Foundation engages with a broad set of partners (academics, non-profit product developers, start-ups, and multinationals) to support the development of innovative drugs and vaccines for global health applications. This talk will highlight additional hurdles, beyond the already substantial challenges inherent in drug development for the developed world, to achieve impact in global health. It will also describe some of the initiatives that the Gates Foundation supports in novel drug delivery technologies for diverse fields ranging from women’s health to HIV prevention to long-acting oral delivery.
Susan Hershenson joined the Bill and Melinda Gates Foundation in 2013 as Deputy Director of Chemistry, Manufacturing and Controls (Integrated Development). She works closely with the foundation’s strategy teams and partners to provide technical expertise and strategic guidance for the therapeutics projects. Dr. Hershenson has over 25 years of experience in drug development. Prior to joining the foundation she founded Pharmaceutical Transformations LLC, a consulting service for the pharmaceutical, biotechnology, drug delivery, and related industries. Her clients included a wide range of biotechnology, pharmaceutical, and drug delivery companies, venture capitalists, university labs, and nonprofit organizations. Before starting her own practice she served in a variety of roles in the biopharmaceutical industry, including most recently Vice President of Pharmaceutical and Device Development at Genentech and Vice President of Pharmaceutics at Amgen. During her career, Dr. Hershenson has made significant contributions to the development and commercialization of numerous therapeutic products including Betaseron®, Stemgen®, Kepivance®, Aranesp®, Neulasta®, Sensipar®, Nplate®, Vectibix®, Prolia®, XGEVA®, and Nutropin AQ® NuSpin™. She earned a B.A. in chemistry from University of Chicago, received her Ph.D. in biochemistry from Yale University, and held a postdoctoral fellowship in the laboratory of Dr. Robert Stroud at University of California, San Francisco. Dr. Hershenson publishes and teaches actively and serves on scientific advisory boards.
Tuesday, July 19
11:15 a.m. - 12:15 p.m.
Moderator: Kinam Park
Jun Keun Chang, CreActive Health Holdings, Korea
Turning Science to Entrepreneurship: A Journey of Passion
This talk focuses on my 20 years of experience as a scientist turned entrepreneur. It was a long journey to transform a start-up company into a company producing products sold throughout the world, but the reward was worth the effort, especially because I enjoyed each step of the way. With such a valuable experience, I started a new company, CreActive Health Holdings, which selects promising technologies for commercialization. CreActive Health Holdings searches for experts with the most advanced technologies in a given field and helps them to accelerate their commercialization by launching new companies as our subsidiaries. The current focus of our company lies in promising novel technologies in new diagnostics and drug delivery system-related theranosis. Development of liquid biopsy has also led to technological advances and commercialization outputs in the diagnostic and therapeutic fields. Since 2015, CreActive Health Holdings has acted as an accelerator and incubator for researchers and professionals in the liquid biopsy sector. Recently, we have launched three subsidiary companies focused on developing 1) diagnosis and prognosis monitoring of breast cancer using an exosome protein biomarker, 2) drugs for photodynamic therapy using drug repositioning technology, and 3) DNA nanocarriers for anticancer chemo drugs and siRNA.
Jun Keun Chang obtained a doctoral degree in biomedical engineering from Seoul National University (SNU), South Korea, in 1995. He worked as a professor in the School of Electrical Engineering at SNU until 2006. He has three books about artificial hearts, 59 papers in peer-reviewed journals, and around 100 international patents for lab-on-a-chip technologies. While a professor at SNU, he founded the venture company Digital Bio Technology and the startup company NanoEnTek for point-of-care medical diagnostics. After the merger of NanoEnTek with SK Telecom, Dr. Chang founded CreActive Health in 2015, and this holding company’s vision is to help innovative biotechnology go to the global market through support from the CreActive Collective Intelligence. Currently, he is working as a member of various committees belonging to academia, society, and government, including Korea’s Presidential Advisory Council on Science and Technology.
Wednesday, July 20
2:00 - 3:00 p.m.
Moderator: Christine Allen
Helen Burt, University of British Columbia, Canada
A Novel Formulation of Docetaxel for Treatment of Non-muscle Invasive Bladder Cancer
Current treatment options for superficial bladder cancer include transurethral resection and intravesical immunotherapy or chemotherapy. A major limitation of intravesical chemotherapy results from the highly impermeable urothelium and rapid washout of the drug following urination, resulting in less than 1% tissue bioavailability. There is a clear unmet need for formulations that improve the residence time and penetration of intravesical agents. We have developed a novel nanoparticulate formulation of docetaxel based on surface amine conjugated, hydrophobically derivatized hyperbranched polyglycerol. The nanoparticles have demonstrated superior efficacy and enhanced bladder tissue uptake in vivo and ex vivo in animal models over the commercial Taxotere® formulation. Preclinical studies will be described.
Helen M. Burt has been serving as the Associate Vice President Research & International in the Office of the Vice President Research & International at the University of British Columbia (UBC) since 2011 and is also the Angiotech Professor of Drug Delivery in the Faculty of Pharmaceutical Sciences at UBC. She was born in Manchester, England, and obtained her B.Pharm. (Hons.) from the University of Bath and her Ph.D. in pharmaceutics from UBC. Her major research efforts involve the development of polymer-based drug delivery systems, in particular micro- and nanoparticulates, for controlled and localized drug delivery.